We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01500499
Recruitment Status : Completed
First Posted : December 28, 2011
Last Update Posted : May 18, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.

Condition or disease Intervention/treatment
Leukemia Genetic: gene expression analysis Genetic: gene rearrangement analysis Genetic: polymerase chain reaction Genetic: protein analysis Genetic: western blotting Other: laboratory biomarker analysis Other: mass spectrometry

Detailed Description:


  • To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells.

OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Role of AF1q in Progression of Leukemia
Study Start Date : December 2011
Primary Completion Date : May 2016

Primary Outcome Measures :
  1. Subcellular localization of the MLL-AF1q fusion protein in leukemia cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Acute myeloid leukemia.


  • Cryopreserved acute myeloid leukemia specimens


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01500499

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Julie D. Saba, MD, PhD Children's Hospital & Research Center Oakland

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01500499     History of Changes
Other Study ID Numbers: AAML12B2
COG-AAML12B2 ( Other Identifier: Children's Oncology Group )
AAML12B2 ( Other Identifier: Children's Oncology Group )
NCI-2012-00099 ( Other Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: December 28, 2011    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016

Keywords provided by Children's Oncology Group:
adult acute myeloid leukemia
childhood acute myeloid leukemia/other myeloid malignancies

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type